All lobbying filings

T1INTERNATIONAL USA

Lobbying for T1INTERNATIONAL USA

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Maine · House · Senate · posted Apr 8, 2025

Official filing document

Bills named in this filing 6

S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1095
Stop STALLING Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1269
INSULIN Act of 2023
S 954
Affordable Insulin Now Act of 2023

Lobbying activity 1

Health Issues

Issues related to the following bills: S. 1040, regarding product hopping; S. 1041, regarding patent evergreening; S. 1095, the Stop STALLING Act; S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act; and a to-be-introduced bill on insulin copays in line with The INSULIN Act of 2023 (S. 1269) and Affordable Insulin Now Act of 2023 (S. 954)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.